Product Cover Similac Pro-Advance Infant Formula with 2'-FL HMO for Immune Support, Ready to Feed Newborn Bottles, 2 fl oz, (48 Count)

Similac Pro-Advance Infant Formula with 2'-FL HMO for Immune Support, Ready to Feed Newborn Bottles, 2 fl oz, (48 Count)

$45.94
$74.97
For Bulk orders
Quantity


  • Features
  • Description
  • Similar Items
IMMUNE SUPPORT: Similac Pro Advance is the first infant formula with 2' FL human milk oligosaccharide,* designed to be closer than ever to breast milk. (*Not from human milk)

NO ARTIFICIAL GROWTH HORMONES: Similac is the first leading infant formula brand with no artificial growth hormones (No significant difference has been shown between milk derived from rbST treated and non rbST treated cows)

REDUCED FUSSINESS: Parents reported reduced fussiness, gassiness, and spit up after 1 day (After switching to Similac Pro Advance)

TRUSTED: Similac is the #1 infant formula brand chosen by moms* and the #1 brand fed in hospitals (*total US infant formula all outlets as of 3/31/18, Nielsen data)

OptiGRO: Our exclusive blend of DHA, Lutein, and Vitamin E, nutrients also found in breast milk, help support baby's brain and eye development
Similac Pro Advance with 2’ FL human milk oligosaccharide* provides immune support by encouraging immune cells to release protective proteins in amounts more like the breastfed baby. It’s also the first leading infant formula with no artificial growth hormones†. Parents reported‡ a reduction in fussiness, gassiness, crying, and spit up after just 1 day of feeding, and the improvement was maintained while feeding the formula. Our exclusive blend of DHA, Lutein, and Vitamin E is important for helping support baby’s brain and eye development. You can trust Similac, the #1 infant formula brand chosen by moms§ and the #1 brand fed in hospitals. *Not from human milk. † No significant difference has been shown between milk derived from rbST treated and non rbST treated cows. ‡After switching to Similac Pro Advance. §Total US infant formula, all outlets as of 3/31/2018, Nielsen data